NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

December 4, 2024

Study Completion Date

August 12, 2026

Conditions

Carcinoma, Non-Small-Cell LungGastric CancerGastroesophageal Junction Cancer

Interventions

DRUG

AZD7789

anti-PD-1 and anti-TIM-3 bispecific antibody

Trial Locations (21)

10029

Research Site, New York

28027

Research Site, Madrid

30322

Research Site, Atlanta

33076

Research Site, Bordeaux

35000

Research Site, Rennes

35575

Research Site, Karşıyaka

37203

Research Site, Nashville

46804

Research Site, Fort Wayne

94805

Research Site, Villejuif

100142

Research Site, Beijing

510060

Research Site, Guangzhou

M5G 2M9

Research Site, Toronto

0112

Research Site, Tbilisi

104-0045

Research Site, Chūōku

277-8577

Research Site, Kashiwa

MD-2025

Research Site, Chisinau

1066 CX

Research Site, Amsterdam

08035

Research Site, Barcelona

06010

Research Site, Ankara

06200

Research Site, Ankara

06800

Research Site, Ankara